3rd Quarter - Report

CENCORA, INC. for CENCORA, INC.

Firm
Client
Income
—
Expenses
$410,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Medicare Part B Reimbursement. Average Sales Price (ASP) generally (in the context of deficit reduction). Medicare Part B Biosimilar Reimbursement. Proposed modifications to the existing definition of distributor bona fide service fees in Medicare Part B. Recognizing pharmacists as providers within Medicare for COVID-19 response. The Equitable Community Access to Pharmacist Services Act (H.R. 1770). Inflation Reduction Act. Supporting Medicare Providers Act (H.R.8800). Medicare Access & CHIP Reauthorization Act (MACRA). Pharmacy and Medically Underserved Areas Enhancement Act. Seniors Access to Critical Medicines Act (H.R. 5526). Protecting Patient Access to Cancer and Complex Therapies Act (S. 2764). Reimbursement policies impacting drug shortages.

LobbyistCovered position, as disclosed
VIVIENNE STAFFORD MITCHELL —
SHELLY MUI-LIPNIK —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: H.R. 8800 (118th), H.R. 5526 (118th), H.R. 1770 (118th), S. 2764 (118th)

Pharmacy PHA

Legislation to provide for coverage under Medicare program of pharmacist services. Pharmacy and Medically Underserved Area Enhancement Act. Medication therapy management. Legislation to prohibit prescription drug plan sponsors and MAPD organizations under Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. House and Senate Agriculture, FDA, and related agency Appropriations bills. House and Senate Labor/HHS appropriations bills. Prescription drug importation. Issues and policies related to generic drug shortages. Recognizing pharmacists as providers within Medicare for COVID-19 response. The Equitable Community Access to Pharmacist Services Act (H.R. 1770/S.2477) and permanent extension of PREP Act Declarations for pharmacist clinical services.

LobbyistCovered position, as disclosed
VIVIENNE STAFFORD MITCHELL —
SHELLY MUI-LIPNIK New —

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 1770 (118th), S. 2477 (118th)

Health Issues HCR

Advancing Emergency Preparedness through One Health Act. Strengthening Americas Strategic National Stockpile Act. Essential Medicines Strategic Stockpile Act. Ensuring essential medication supply for military and Department of Defense. National Defense Authorization Act. digital communication of prescribing information. Prescription Information Modernization Act. Implementation of Consolidated Appropriations Act. Drug Shortages. H.R. 501 - Block, Report and Suspend Suspicious Shipments Act. Pandemic and All Hazards Preparedness Reauthorization. Drug Supply Chain Security Act Implementation (DSCSA). Rolling Active Pharmaceutical Ingredient and Drug (RAPID) Reserve Act (S. 2510). SUPPORT Act Reauthorization. FY 2024 National Defense Authorization Act. Medical and Health Stockpile Accountability Act of 2023 (H.R.3577). Drug Origin Transparency Act of 2023 (H.R. 3810). E&C and Finance Request for Information (RFI) to Inform Policymaking on Drug Shortages. House E&C Drug Shortages Discussion Draft.

LobbyistCovered position, as disclosed
VIVIENNE STAFFORD MITCHELL —
SHELLY MUI-LIPNIK New —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; Food & Drug Administration (FDA)

Bills named: H.R. 501 (118th), H.R. 3577 (118th), H.R. 3810 (118th), S. 2510 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.